BreezeBio

Executive Summary

BreezeBio is a San Diego-based biotechnology company focused on precision genetic medicines for autoimmune diseases and oncology, leveraging its proprietary NanoGalaxy® platform. This platform uses non-immunogenic nanoparticles to deliver genetic payloads specifically to immune cells, addressing a key challenge in the field: targeted delivery. The company's lead program aims to induce antigen-specific immune tolerance in Type 1 Diabetes, a novel approach with the potential to halt or reverse disease progression. Founded in 2021, BreezeBio is privately held and has not disclosed funding or valuation. Its technology could have broad applications beyond diabetes, including other autoimmune conditions and cancer immunotherapy, positioning it as a potential platform play in the growing cell and gene therapy space.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round65% success
• Q4 2026Preclinical Proof-of-Concept Data for Type 1 Diabetes Program60% success
• H2 2027Strategic Partnership or Licensing Deal for NanoGalaxy® Platform40% success